Phenotypic alterations of small cell lung carcinoma induced by different levels of wild-type p53 expression

Cell Death and Differentiation

Volumn 5, Issue 2, 1998, Pages 148-155

  Adachi, Jun Ichi ^a   Ookawa, Keizou ^b   Kohno, Takashi ^a   Tomizawa, Yoshio ^a   Tsuchida, Shigeki ^b   Yokota, Jun ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Apoptosis; G1 arrest; Lung carcinoma; p53

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TETRACYCLINE;

ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL GROWTH; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0031851002     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400325     Document Type: Article

References (41)

1. Adachi J, Ookawa K, Shiseki M, Okazaki T, Tsuchida S, Morishita K and Yokota J (1996) Induction of apoptosis but not G1 arrest by expression of the wild-type p53 gene in small cell lung carcinoma Cell Growth Differ. 7: 879-886
2. Baker SJ, Markowrtz S, Fearon ER, Willson JK and Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249 912-915
3. Bargou RC, Bommert K, Weinmann P, Daniel PT, Wagener C, Mapara MY and Dorken B (1995) Induction of Bax-alpha precedes apoptosis in a human B lymphoma cell line: potential role of the bcl-2 gene family in surface IgM-mediated apoptosis. Eur. J Immunol 75: 770-775
4. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsuya T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF and Linnoila RI (1992) Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation Oncogene 7: 743-749
5. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G and Thompson CB (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic death. Cell 74: 597-608
6. Chen PL, Chen Y, Bookstein R and Lee WH (1990) Genetic mechanisms of tumor suppression by the human p53 gene. Science 250: 1576-1580
7. Chen X, Ko LJ, Jayaraman L and Prives C (1996) p53 levels, functional domains. and DNA damage determine the extent of the apoptotic response of tumor cells. Genes & Dev. 10: 2438-2451
8. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH and Reid BJ (1995) A p53-dependent mouse spindle checkpoint. Science 267: 1353-1356
9. DiLeonardo A, Linke SP, Clarkin K and Wahl GM (1994) DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip 1 in normal human fibroblasts Genes & Dev 8: 2540-2551
10. Diller L, Kassel L, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein Band Friend SH (1990) p53 functions as a cell cycle control protein in osteosarcomas Mol. Cell Biol 10: 5772-5781
11. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
12. Gossen M and Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad. Sci. USA 89: 5547-5551
13. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is apotent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816
14. Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) p53 mutations in human cancers. Science 253: 49-53
15. WAF1/CIP1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis. Oncogene 11 2311-2315
16. Ko LJ and Prives C (1996) p53: puzzle and paradigm. Genes & Dev. 10: 1054-1072
17. Kuerbitz SJ, Plunkett BS, Walsh WV and Kasten MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation Proc Natl. Acad. Sci USA 89: 7491-7495
18. Levine AJ, Momand J and Finlay CA (1991) The p53 tumor suppressor gene. Nature 351: 453-456
19. 1 phase. Proc. Natl. Acad. Sci USA 89: 9210-9214
20. McCurrach ME, Connor TMF, Knudson CM and Korsmeyer SJ (1997) bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl. Acad. Sci. USA 94: 2345-2349
21. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW and Ullrich SJ (1990) Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53 Proc. Natl. Acad. Sci. USA 87: 6166-6170
22. Miyashita T, Harigai M, Hanada M and Reed JC (1994a) Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131-3135
23. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC (1994b) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805
24. Miyashita T and Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299
25. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity J Immunol Meth. 65: 55-63
26. Oltvai ZN, Milliman CL and Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 74: 609-619
27. Ookawa K, Shiseki M, Takahashi R, Yoshida Y, Terada M and Yokota J (1993) Reconstitution of the RB gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations. Oncogene 8: 2175-2181
28. Ookawa K, Tsuchida S, Adachi J and Yokota J (1997) Differentiation induced by RB expression and apoptosis induced by p53 expression in an osteosarcoma cell line. Oncogene 14: 1389-1396
29. Polyak K, Waldman T, He TC, Kinzler KW and Vogelstein B (1996) Genetic determinants of p53-induced apoptosis and growth arrest. Genes & Dev. 10: 1945-1952
30. Sabbatini P, Han J, Chiou SK, Nicholson DW and White E (1997) Interleukin 1β converting enzyme-like proteases are essential for p53-mediated transcriptionally dependent apoptosis. Cell Growth Differ. 8: 643-653
31. Sameshima Y, Matsuno Y, Hirohashi S, Shimosato Y, Mizoguchi H, Sugimura T, Terada M and Yokota J (1992) Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene 7: 451-457
32. L protects cancer cells from p53-mediated apoptosis. Oncogene 11: 1389-1394
33. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B and Costa J (1992) Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad Sci, USA 89: 4495-4499
34. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF and Minna JD (1989) p53: a frequent target for genetic abnormalities in lung cancer Science 246: 491-494
35. Vogelstein B and Kinzler KW (1992) p53 function and dysfunction. Cell 170: 523-526
36. Xiang J, Chao DT and Korsmeyer SJ (1996) BAX-induced cell death may not require interleukin 1β-converting enzyme-like proteases. Proc. Natl. Acad. Sci. USA 93: 14559-14563
37. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704
38. Yin C, Knudson CM, Korsmeyer SJ and Van Dyke T (1997) Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385: 637-640
39. Yin XM, Oltvai ZN and Korsmeyer SJ (1994) BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimenzation with Bax. Nature 369: 321-323
40. Yonish-Rouach E, Resnitzky D, Lottem J, Sachs L, Kimchi Aand Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345-347
41. Zieve GW, Turnbull D, Mullins JM and McIntosh JR (1980) Production of large numbers of mitotic mammalian cells by use of the reversible microtubule inhibitor nocodazol. Exp. Cell Res. 126: 397-405